Jan A. Burger

Internal Medicine

210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 323 publications

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Journal: Blood cancer journal

Published: April 12, 2026

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Journal: Blood advances

Published: February 25, 2026

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Journal: Blood advances

Published: February 25, 2026

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Journal: Leukemia

Published: December 10, 2025

Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Journal: Blood cancer discovery

Published: October 18, 2025

Mutational Landscape and Clinical Impact of SPEN Mutations in Patients with Chronic Lymphocytic Leukemia.

Mutational Landscape and Clinical Impact of SPEN Mutations in Patients with Chronic Lymphocytic Leukemia.

Journal: Cancers

Published: September 17, 2025

Clinical, genetic, and familial features of POT1 tumor predisposition syndrome.

Clinical, genetic, and familial features of POT1 tumor predisposition syndrome.

Journal: Cancer

Published: July 24, 2025

Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia.

Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia.

Journal: Blood neoplasia

Published: June 18, 2025

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Journal: Blood

Published: January 16, 2025

Properties of Cosmic Lithium Isotopes Measured by the Alpha Magnetic Spectrometer.

Properties of Cosmic Lithium Isotopes Measured by the Alpha Magnetic Spectrometer.

Journal: Physical review letters

Published: December 19, 2024

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Journal: Leukemia

Published: November 25, 2024

Solar Modulation of Cosmic Nuclei over a Solar Cycle: Results from the Alpha Magnetic Spectrometer.

Solar Modulation of Cosmic Nuclei over a Solar Cycle: Results from the Alpha Magnetic Spectrometer.

Journal: Physical review letters

Published: October 09, 2024

Showing 1-12 of 323

Last Updated: 09/26/2026